GlassScriptPhysician profile
Gerald V Curley
NPI 1417919754
$5,772.60
in general payments reported to CMS, 2019-2025
42 companies · $571 in 2025
The $571 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $674 · 2020: $690 · 2021: $1,192 · 2022: $940 · 2023: $1,007 · 2024: $698 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,276.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,509.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $546.49 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $497.94 | 2019-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $379.32 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $346.10 | 2019-2025 | |
| Amarin Pharma, INC. | $331.27 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $259.09 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $224.20 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.16 | 2019-2022 | |
| Abbvie INC. | $180.54 | 2019-2024 | Ubrelvy |
| Medtronic, INC. | $168.82 | 2024 | Reveal Linq |
| Novartis Pharmaceuticals Corporation | $128.71 | 2019-2023 | |
| Esperion Therapeutics, INC. | $101.33 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $76.80 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.39 | 2019-2023 | Xifaxan |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Curley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.